evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 0 · 0%High 1 · 25%

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review